MoonLake Immunotherapeutics (MLTX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$196.01M | -68.1% |
| 2024 | -$116.59M | -172.5% |
| 2023 | -$42.78M | +23.5% |
| 2022 | -$55.89M | -9046.9% |
| 2021 | -$611.1K | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$196.01M | -68.1% |
| 2024 | -$116.59M | -172.5% |
| 2023 | -$42.78M | +23.5% |
| 2022 | -$55.89M | -9046.9% |
| 2021 | -$611.1K | — |